Debt-to-equity of ALPINE IMMUNE SCIENCES, INC. from 30 Jun 2018 to 31 Mar 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
ALPINE IMMUNE SCIENCES, INC. quarterly Debt-to-equity in % history and change rate from 30 Jun 2018 to 31 Mar 2024.
  • ALPINE IMMUNE SCIENCES, INC. Debt-to-equity for the quarter ending 31 Mar 2024 was 26%, a 62% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

ALPINE IMMUNE SCIENCES, INC. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2024 26% -42% -62% 31 Mar 2024
Q4 2023 37% -41% -53% 31 Dec 2023
Q3 2023 53% -39% -42% 30 Sep 2023
Q2 2023 56% -49% -46% 30 Jun 2023
Q1 2023 68% -52% -43% 31 Mar 2023
Q4 2022 78% -50% -39% 31 Dec 2022
Q3 2022 93% -44% -32% 30 Sep 2022
Q2 2022 105% -55% -34% 30 Jun 2022
Q1 2022 119% -47% -28% 31 Mar 2022
Q4 2021 129% -35% -22% 31 Dec 2021
Q3 2021 137% -25% -15% 30 Sep 2021
Q2 2021 159% +1.8% +1.1% 30 Jun 2021
Q1 2021 167% +89% +115% 31 Mar 2021
Q4 2020 164% +110% +204% 31 Dec 2020
Q3 2020 161% +120% +288% 30 Sep 2020
Q2 2020 157% +130% +477% 30 Jun 2020
Q1 2020 77% +61% +367% 31 Mar 2020
Q4 2019 54% +40% +290% 31 Dec 2019
Q3 2019 42% +31% +290% 30 Sep 2019
Q2 2019 27% +18% +200% 30 Jun 2019
Q1 2019 17% 31 Mar 2019
Q4 2018 14% 31 Dec 2018
Q3 2018 11% 30 Sep 2018
Q2 2018 9.1% 30 Jun 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.